| __timestamp | Incyte Corporation | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3004000 | 205018000 |
| Thursday, January 1, 2015 | 26972000 | 392709000 |
| Friday, January 1, 2016 | 58187000 | 299694000 |
| Sunday, January 1, 2017 | 79479000 | 397061000 |
| Monday, January 1, 2018 | 94123000 | 434100000 |
| Tuesday, January 1, 2019 | 114249000 | 782200000 |
| Wednesday, January 1, 2020 | 131328000 | 1119900000 |
| Friday, January 1, 2021 | 150991000 | 2437500000 |
| Saturday, January 1, 2022 | 206997000 | 1560400000 |
| Sunday, January 1, 2023 | 255000000 | 1815800000 |
| Monday, January 1, 2024 | 312068000 | 1970500000 |
Unlocking the unknown
In the competitive world of biotechnology, understanding the cost of revenue is crucial for evaluating a company's financial health. Over the past decade, Regeneron Pharmaceuticals, Inc. and Incyte Corporation have shown distinct trajectories in their cost of revenue. From 2014 to 2023, Regeneron's cost of revenue surged by approximately 785%, peaking at nearly $1.82 billion in 2023. In contrast, Incyte's cost of revenue increased by a staggering 8,400%, reaching $255 million in the same year. This stark difference highlights Regeneron's larger scale of operations compared to Incyte. The data reveals that while both companies have grown, Regeneron's cost structure is significantly higher, reflecting its expansive product portfolio and market reach. As the biotech industry continues to evolve, these financial insights provide a window into the strategic decisions shaping the future of these two industry leaders.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Regeneron Pharmaceuticals, Inc. and Dyne Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Incyte Corporation vs Dyne Therapeutics, Inc.
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored